侧漏而已

今年ASCO Incy有15个Abstracts。。。大部分都是关于IDO抑制剂Epacadostat的。

官方说
“These abstracts highlight the depth and potential of our growing clinical development portfolio of both immuno-oncology and targeted therapies,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “We are especially pleased to have new data from the ECHO-202 trial evaluating epacadostat plus pembrolizumab and initial data from the ECHO-204 trial evaluating epacadostat plus nivolumab accepted. These data contributed to our recent decisions to initiate additional pivotal Phase 3 studies with Merck and BMS.”

其中亮点是CMO说非常高兴能分享这些数据。这些数据能说明我们为什么开这么多3期。。。
说明数据估计比较亮眼。。

什么情况为什么大跌

这还翻车，，

10%不算翻车，搞不好过两天被收购了。